Proteonomix, Inc. (PROT) Notes Progress in Proteoderm Distribution and Advancement of UMK-121
(firmenpresse) - MOUNTAINSIDE, NJ -- (Marketwire) -- 08/23/11 -- PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that it has made substantial progress in arranging the distribution of its Proteoderm line of cosmeceutical products.
Michael Cohen, President of the Company, stated: " products represent the state-of-the-art in anti-aging science. We have been holding discussions with several distributors and are nearing potential agreement on several fronts that should result in the launch of the products into the retail arena in the near future."
Dr. Ian McNiece, Proteonomix Chief Scientific Officer, noted: "Our UMK-121 pharmaceutical therapy is advancing toward clinical trials in ESLD ('End Stage Liver Disease') patients. The Company hopes to provide more information on this product in the early part of the fourth quarter. The Company is working diligently to advance this product line into a clinical trial."
About Proteonomix, Inc.:
Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. The Proteonomix Family of companies includes Proteoderm, StromaCel, National Stem Cell, PRTMI, The Sperm Bank of New York and THOR Biopharma. Proteoderm, Inc. is a wholly owned subsidiary that has developed an anti-aging line of skin care products. StromaCel, Inc. develops therapeutic modalities for the treatment of Cardiovascular Disease (CVD). The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. ("PRTMI") intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies. Please also visit , , and .
Forward-looking statements:
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made.
Contact:
Proteonomix, Inc.
Michael Cohen
CEO
Phone: +1-973-544-6116
Email:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 23.08.2011 - 07:15 Uhr
Sprache: Deutsch
News-ID 1032948
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
MOUNTAINSIDE, NJ
Phone:
Kategorie:
Women's Interest
Anmerkungen:
Diese Pressemitteilung wurde bisher 177 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Proteonomix, Inc. (PROT) Notes Progress in Proteoderm Distribution and Advancement of UMK-121
"
steht unter der journalistisch-redaktionellen Verantwortung von
Proteonomix (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
